Literature DB >> 10545479

Expression of the Bcl-2 family member A1 is developmentally regulated in T cells.

M M Tomayko1, J A Punt, J M Bolcavage, S L Levy, D M Allman, M P Cancro.   

Abstract

During T cell development, cells that fail to meet stringent selection criteria undergo programmed cell death. Thymocyte and peripheral T cell susceptibility to apoptosis is influenced by expression of Bcl-2 family members, some of which are expressed in a developmentally patterned manner. We previously showed developmentally regulated expression of A1, an anti-apoptotic Bcl-2 family member, among B cell developmental subsets. Here we show that cells of the T lineage also express A1 in a developmentally regulated manner. Both A1 mRNA and A1 protein are readily detectable in the thymus, and while present among DN cells, A1 mRNA is up-regulated to very high levels among double-positive (DP) thymocytes. It is then down-regulated to moderate levels among single-positive (SP) thymocytes, and finally expressed at approximately 25-fold lower levels among mature SP CD4(+) and CD8(+) lymph node T cells than among DP thymocytes. Furthermore, we find that in vitro TCR ligation up-regulates A1 expression among both DP and SP thymocytes. Together, these data show that A1 expression is developmentally regulated in T lymphocytes and is responsive to TCR signaling, suggesting that A1 may play a role in maintaining the viability of DP thymocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545479     DOI: 10.1093/intimm/11.11.1753

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection.

Authors:  Selma Tuzlak; Robyn L Schenk; Ajithkumar Vasanthakumar; Simon P Preston; Manuel D Haschka; Dimitra Zotos; Axel Kallies; Andreas Strasser; Andreas Villunger; Marco J Herold
Journal:  Cell Death Differ       Date:  2017-01-13       Impact factor: 15.828

3.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 4.  Insights into thymic involution in tumor-bearing mice.

Authors:  Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 5.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 6.  Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Authors:  Maja Sochalska; Selma Tuzlak; Alexander Egle; Andreas Villunger
Journal:  FEBS J       Date:  2015-01-23       Impact factor: 5.542

7.  Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection.

Authors:  K J Campbell; D H D Gray; N Anstee; A Strasser; S Cory
Journal:  Cell Death Differ       Date:  2012-06-29       Impact factor: 15.828

8.  Fc gamma RI-mediated activation of human mast cells promotes survival and induction of the pro-survival gene Bfl-1.

Authors:  Mats Karlberg; Zou Xiang; Gunnar Nilsson
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

Review 9.  A1/Bfl-1 in leukocyte development and cell death.

Authors:  Eleonora Ottina; Denise Tischner; Marco J Herold; Andreas Villunger
Journal:  Exp Cell Res       Date:  2012-02-04       Impact factor: 3.905

10.  Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?

Authors:  I Rebollo-Mesa; E Nova-Lamperti; P Mobillo; M Runglall; S Christakoudi; S Norris; N Smallcombe; Y Kamra; R Hilton; S Bhandari; R Baker; D Berglund; S Carr; D Game; S Griffin; P A Kalra; R Lewis; P B Mark; S Marks; I Macphee; W McKane; M G Mohaupt; R Pararajasingam; S P Kon; D Serón; M D Sinha; B Tucker; O Viklický; R I Lechler; G M Lord; M P Hernandez-Fuentes
Journal:  Am J Transplant       Date:  2016-08-08       Impact factor: 8.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.